Mizuho analyst Anthony Petrone raised the firm’s price target on MiMedx to $14 from $12 and keeps a Buy rating on the shares. The analyst says last week’s final local coverage decisions for skin substitute graft from three Medicare administrative contractors could be a “potential boon” for Epifix.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDXG:
- MiMedx price target raised to $12 from $10 at Mizuho
- MiMedx price target raised to $11 from $8 at H.C. Wainwright
- MiMedx sees FY23 revenue up mid-to-upper teens percent range, consensus $305.99M
- MiMedx reports Q2 EPS 0c, consensus (2c)
- MIMEDX Announces Second Quarter 2023 Operating and Financial Results